Technology
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
Published
1 year agoon
By
Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19
NEW YORK, May 15, 2025 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.
“BrainStorm continues to make meaningful progress in advancing our NurOwn® development program. Our priority continues to be initiation of a Phase 3b trial, designed to confirm the product’s efficacy in early stage ALS patients and support a new BLA,” said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. “We have a clear path forward and ongoing support from the ALS community. We recently submitted an amendment to our IND, which includes updated documentation that is essential for regulatory compliance and trial integrity. We are in the process of finalization clinical trial agreements with leading academic centers and completing other necessary steps on trial execution and manufacturing. We believe that NurOwn, if approved, has the potential to become a valuable treatment option for ALS patients. Our team is fully aligned and executing with discipline to position BrainStorm for success.”
Recent Highlights
NurOwn (MSC-NTF) for ALS
IND amendment on NurOwn submitted to FDA BrainStorm submitted an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration for NurOwn. This important milestone sets the stage for the initiation of the planned Phase 3b clinical trial, which has been designed in collaboration with the FDA under a Special Protocol Assessment (SPA). The trial will have a primary efficacy endpoint assessing changes in ALSFRS-R scores from baseline to week 24, and is designed to enroll approximately 200 ALS participants with early stage disease. Successful completion of the double blind part of the study (Part A) is expected to generate the clinical data to support a new BLA submission.
Phase 3b trial listed on Clinicaltrials.gov. Details of the trial, known as ENDURANCE, are now available on ClinicalTrials.gov ID NCT06973629. Included is a list of 15 clinical trial sites that are expected to participate in the trial.
NurOwn® data selected as Breakthrough Science for Presentation at ISCT 2025 Meeting The new pharmacogenomic were delivered in a oral presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for ALS patients treated with NurOwn. The presentation was featured in the ISCT public announcement regarding the meeting, which indicated that the data were “carefully reviewed and selected by the ISCT 2025 Planning Faculty, to explore the latest breakthroughs in the clinical translation of Mesenchymal Stem/Stromal Cells and how they will shape the future of cell therapies.”
Biomarker insights supporting NurOwn’s mechanism and clinical impact presented at the 2025 ALS Drug Development Summit BrainStorm’s senior leadership team (Dr. Bob Dagher, Dr. Netta Blondheim-Shraga and May Kay Turner) participated in sessions at the summit that highlighted insights and expertise gained throughout the NurOwn® development program. These sessions included a presentation on cerebrospinal fluid (CSF) biomarker pathways associated with NurOwn treatment, including their relationship to clinical outcomes and disease heterogeneity in ALS.
Financial Results for the First Quarter Ended March 31, 2025
Cash, cash equivalents, and restricted cash were approximately $1.8 million as of March 31, 2025.Research and development expenditures, net, for the quarter ended March 31, 2025 were $1.3 million, compared to $1.0 million for the quarter ended March 31, 2024.General and administrative expenses for the quarter ended March 31, 2025 were approximately $1.8 million, compared to approximately $1.5 million for the quarter ended March 31, 2024.Net loss for the quarter ended March 31, 2025, was approximately $2.9 million, as compared to a net loss of approximately $3.4 million for the quarter ended March 31, 2024.Net loss per share for the three months ended March 31, 2025, and 2024 was $0.45 and $0.75, respectively.
Conference Call and Webcast
Monday, May 19, 2025, at 8:30 a.m. U.S. Eastern Time
Participant Numbers:
U.S. dial in: 888-506-0062
International: 973-528-0011
Participant Access Code: 621608
Webcast URL: https://www.webcaster4.com/Webcast/Page/2354/52457
The replay of the conference call can be accessed by dialing the numbers below and will be available for 14 days.
Teleconference Replay Number:
Toll Free: 877-481-4010
International: 919-882-2331
Passcode: 52457
The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company’s proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
NurOwn® is BrainStorm’s lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the “Floor Effect” — a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm’s growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.
Notice Regarding Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management’s ability to successfully achieve its goals, BrainStorm’s ability to raise additional capital, BrainStorm’s ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm’s future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
Investors:
Michael Wood
Phone: +1 646-597-6983
mwood@lifesciadvisors.com
Media:
Uri Yablonka, Chief Business Officer
Phone: +1 917-284-2911
uri@brainstorm-cell.com
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
(Except share data)
March 31,
December 31,
2025
2024
Unaudited
Audited
U.S. $ in thousands
ASSETS
Current Assets:
Cash and cash equivalents
$
1,644
$
187
Other accounts receivable
67
63
Prepaid expenses and other current assets
621
135
Total current assets
$
2,332
$
385
Long-Term Assets:
Prepaid expenses and other long-term assets
$
22
$
22
Restricted Cash
182
184
Operating lease right of use asset (Note 4)
653
807
Property and Equipment, Net
382
434
Total Long-Term Assets
$
1,239
$
1,447
Total assets
$
3,571
$
1,832
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities:
Accounts payables
$
6,797
$
6,080
Accrued expenses
538
619
Short-term loans (Note 7)
1,200
300
Operating lease liability (Note 4)
443
549
Employees related liability
1,923
1,430
Total current liabilities
$
10,901
$
8,978
Long-Term Liabilities:
Operating lease liability (Note 4)
127
171
Warrants liability (Note 5)
–
447
Total long-term liabilities
$
127
$
618
Total liabilities
$
11,028
$
9,596
Stockholders’ Deficit:
Stock capital: (Note 6)
15
14
Common Stock of $0.00005 par value – Authorized: 250,000,000 shares at March 31, 2025 and at
December 31, 2024 respectively; Issued and outstanding: 7,911,204 and 6,141,762 shares at March
31, 2025 and December 31, 2024 respectively (*)
Additional paid-in-capital
222,144
218,974
Treasury stocks
(116)
(116)
Accumulated deficit
(229,500)
(226,636)
Total stockholders’ deficit
$
(7,457)
$
(7,764)
Total liabilities and stockholders’ deficit
$
3,571
$
1,832
The accompanying notes are an integral part of the consolidated financial statements.
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)
U.S. dollars in thousands
(Except share data)
Three months ended
March 31,
2025
2024
Unaudited
Operating expenses:
Research and development, net
$
1,304
$
961
General and administrative
1,785
1,513
Operating loss
(3,089)
(2,474)
Financial income, net
46
13
Loss on change in fair value of Warrants liability (Note 6)
(179)
(940)
Net loss
$
(2,864)
$
(3,401)
Basic and diluted net loss per share from continuing operations
$
(0.45)
$
(*) (0.75)
Weighted average number of shares outstanding used in computing
basic and diluted net loss per share
6,342,002
(*) 4,315,903
The accompanying notes are an integral part of the consolidated financial statements.
Logo: https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-first-quarter-2025-financial-results-and-provides-corporate-update-302456908.html
SOURCE BrainStorm Cell Therapeutics Inc.
You may like
Technology
Northwood raises $375 million to build the network connecting satellites to Earth
Published
3 minutes agoon
November 2, 2026By
Funding will scale the company’s shared, multi-orbit ground network for commercial, U.S. government, and allied customers
TORRANCE, Calif., Nov. 2, 2026 /PRNewswire/ — Northwood Space Corp. (“Northwood”), the company building the network connecting satellites to Earth, today announced it has closed a $375 million Series C equity financing round. The funding will accelerate delivery on existing contracts, talent acquisition, and the buildout of Northwood’s global ground network for commercial, U.S. government, and allied space missions.
Since its Series B less than nine months ago, Northwood has deployed six multi-orbit-capable sites on two continents, demonstrated geosynchronous command capacity from a commercial phased array in live tests, developed and launched a high-throughput antenna system, and opened a new 185,000-square-foot headquarters and factory in Torrance, expanding its manufacturing footprint more than fivefold. Northwood has also added new customers and contracts across U.S. government agencies, commercial new-space operators, and traditional satellite operators.
Andreessen Horowitz (a16z) and DFJ Growth co-led the round, with participation from Alpine Space Ventures, Washington Harbour Partners, Stepstone Activate, In-Q-Tel (IQT), and others. A separate multi-year credit facility from HSBC Innovation Banking will also support working capital and network expansion.
“Space began as the frontier of human innovation, and communications sits at the heart of every mission, yet it has been neglected for decades,” said Bridgit Mendler, co-founder and CEO of Northwood. “We have built hardware that performs and a network that can support the most demanding missions. This funding lets us scale that network and build the infrastructure the next generation of space missions will depend on.”
“We’ve backed Northwood in every round since seed because we believe ground infrastructure is essential to making space infrastructure more abundant,” said Katherine Boyle, board director of Northwood and general partner at Andreessen Horowitz. “Northwood is building the ground network of the future and has become an indispensable partner to government and commercial customers alike.”
“What goes up must come down … this is a universal truth of sending data to and from space-based networks. Northwood plays an essential role in an oft-forgotten, yet critical segment, of that ecosystem — purpose-built to ensure mission-critical signals are delivered to and from satcom constellations reliably and securely. Northwood has emerged from a raw startup to a new-generation leader over the past year, changing the game with innovation and speed of execution to quickly surpass legacy incumbents,” according to Randy Glein, Founder and Managing Partner at DFJ Growth. “Northwood’s advanced phased array technologies, innovative systems, and vertically-integrated manufacturing approach are delivering robust capabilities to demanding commercial and government customers. We are thrilled to join the team at Northwood!”
The ground has become the bottleneck
Satellites are multiplying and spreading across orbits. Active satellites have grown from about 3,000 in 2020 to more than 14,000 by the end of 2025, with tens of thousands more projected by 2030, but the ground infrastructure they rely on was built for a different era of space and has not kept pace. Missions need more ground capacity, in more places, with more capabilities. Meeting the demand takes ground infrastructure that can serve multiple satellites at once, support multiple orbits, and deploy in months rather than years. Without modern infrastructure, the ground will limit what we can do in space, from satellite communications to Earth observation, from national security missions to cislunar exploration.
A space network built like infrastructure
Northwood designs and manufactures its own modular antennas in Torrance, California: Portal phased arrays for command and control and Prism high-throughput dishes for payload data. At full production, the company can build hundreds of antennas per year, and each system ships by standard freight and needs only flat ground, power, and fiber, with none of the extensive civil works traditional ground stations require.
Northwood’s own software and proprietary techniques combine multiple antennas into larger effective apertures. In a recent milestone, the company arrayed 10 Portals to achieve the receive performance of a 20-foot dish. That software extends to a modern API that lets satellite operators search, reserve, update, and cancel passes on the network, paired with hands-on Mission Architects who guide each customer from first conversation through deployment. Operators get a live link without building ground infrastructure of their own.
Because Northwood controls the full stack, from antenna hardware to site selection and buildout to scheduling software, space operators book the capacity they need on a shared network instead of spending millions of dollars on dedicated ground stations. And because the antennas are standardized and modular, the network is growing quickly: a new site takes three months rather than years, and new antennas go from truck arrival to live links in three to four hours. For select customers, Northwood also sells its antenna systems directly, the same hardware that powers the shared network.
Momentum since the Series B
Demonstrated multi-orbit, from LEO to GEO. Northwood demonstrated its multi-orbit capability in a prototype for the U.S. Space Force, delivering dedicated satellite command capacity as a service to geostationary orbit. The demonstration included a full-duplex link to a government GEO satellite from a Northwood Portal phased-array site, building on the company’s existing LEO demonstrations.High-throughput links. Northwood released Prism, a parabolic dish built for multi-gigabit links. Together with Portal, Prism will take the network to global coverage, with sites capable of 100+ Gbps in high-demand regions by the end of 2027.Production at scale. The company’s new 185,000-square-foot Torrance headquarters and factory, opened in September 2026, will produce hundreds of antennas and other components per year across dedicated production lines.Customers. Northwood has added new customers and contracts across U.S. government agencies, commercial new-space operators, and traditional satellite operators.Team. Northwood has grown to more than 140 employees and plans to add 400 jobs in Torrance and Washington, DC over three years across RF engineering, manufacturing, software and site operations.
This announcement is only the start. Northwood is rebuilding the full network stack for bringing data to, through, and from orbit, with several site and network expansions to be announced in the first half of 2027.
About Northwood
Northwood builds the network connecting satellites to Earth. Based in Torrance, California, the company combines modular antenna hardware, manufacturing, software, and global site operations into a shared ground network serving commercial, U.S. government, and allied customers. Northwood helps satellite operators establish and expand connectivity across orbits, supporting reliable communications as their missions grow. Learn more at northwoodspace.io. See open roles at northwoodspace.io/careers.
Media Contact
press@northwoodspace.io
View original content to download multimedia:https://www.prnewswire.com/news-releases/northwood-raises-375-million-to-build-the-network-connecting-satellites-to-earth-302925872.html
SOURCE Northwood Space
Technology
Cleafy Named a Leader in QKS Group SPARK Matrix™: Enterprise Fraud Management, 2026
Published
3 minutes agoon
November 2, 2026By
The QKS Group SPARK Matrix™ evaluates enterprise fraud management providers across Technology Excellence and Customer Impact.Cleafy is recognized for its cyber-fraud convergence approach, real-time attack visibility, and explainable fraud detection capabilities.
PUNE, India, Nov. 2, 2026 /PRNewswire/ — QKS Group announced today that it has named Cleafy as a leader in the SPARK Matrix™: Enterprise Fraud Management, 2026.
Anandh Ramaswamy, Practice Director at QKS Group, states, “Fraud increasingly begins as a cyberattack, well before a payment is initiated. Our assessment finds Cleafy particularly compelling in connecting these stages through its Fraud xDR approach, which brings device, malware, network, session, and transaction evidence into a continuous view of how an attack develops. Its deterministic micro-models and Attack Pattern Reconstruction help banks recognize account takeover, remote-access abuse, and payment scams earlier, with clear reasons for intervention rather than an isolated risk score. For institutions with substantial digital banking activity, this cyber-fraud convergence can strengthen prevention while supporting more proportionate customer interventions. Buyers should assess Cleafy as an attack-focused complement to their broader fraud controls, particularly where visibility before the transaction is a priority.”
Divya Baranawal, Vice President and Principal Analyst at QKS Group, states, “Cleafy’s Leader position reflects a distinctive approach to Enterprise Fraud Management: connecting cybersecurity intelligence with fraud operations rather than treating them as separate detection functions. Cleafy LABS contributes specialist threat research and intelligence, while Fraud xDR connects evidence across the digital journey to reveal how attacks develop. Cleafy Nyx builds on this foundation, autonomously hunting for emerging threats and connecting activity across sessions, accounts and devices, with recommended responses subject to institutional oversight. This combination is relevant for banks facing coordinated attacks and growing investigation volumes. Our evaluation also highlights the importance of validating channel coverage, integration requirements, and local service readiness against each institution’s operating environment.”
QKS Group defines Enterprise Fraud Management as the technologies and operational processes used to detect, prevent, investigate, and respond to fraud across customer interactions and transactions. As digital fraud increasingly combines compromised devices, malicious software, manipulated sessions, and payment activity, effective programs need to connect cyber and financial signals, apply timely risk controls, and equip investigators with auditable evidence. Evaluation therefore extends beyond transaction scoring to detection coverage, explainability, investigation workflows, deployment, and measurable customer impact.
Cleafy’s differentiation lies in its cyber-origin view of financial fraud. Its Fraud xDR approach transforms diverse device, application, network, malware, behavioural, and transaction signals into structured, connected evidence across digital banking journeys. Deterministic micro-models provide explainable detection indicators, Cleafy LABS contributes specialist threat intelligence, and Cleafy Nyx autonomously hunts for emerging threats, connecting evidence into coordinated attacks and recommending responses for analyst review. This architecture is especially relevant to banks prioritizing account takeover, banking malware, remote-access fraud, and authorized push payment scams. Buyers should validate fit with existing payment controls, required channels, and governance arrangements.
The QKS Group SPARK Matrix™ includes a detailed analysis of the global market dynamics, major trends, vendor landscape, and competitive positioning. The study also provides a competitive analysis and ranking of the Enterprise Fraud Management, 2026 providers in the form of the SPARK Matrix™. The study also provides strategic information for users to evaluate different vendor capabilities, competitive differentiation, and market positions.
“Maintaining our Leader position, and improving on it, reflects the value of the approach we’ve built,” said Michael Morris, Product Director at Cleafy. “We brought the discipline of cybersecurity into fraud prevention to recognise attacks before they become fraudulent transactions. With Nyx, we’re taking that further through Autonomous Fraud Operations, continuously hunting for emerging threats and giving banks the evidence they need to act earlier, with greater precision and efficiency.”
Additional Resources:
For more information about Cleafy, visit Here. SPARK Matrix™ Enterprise Fraud Management, 2026
About Cleafy
Cleafy helps banks stop financial fraud through Autonomous Fraud Operations. Rather than adding another tool for analysts, Cleafy investigates cases, produces evidence-based decisions and adapts to changing criminal tactics in production. European banks have been running Cleafy’s Autonomous Fraud Operations since December 2025, enabling fraud teams to prevent more fraud losses while focusing human expertise where it adds the greatest value.
Media Contact:
www.cleafy.com
Tammy du Preez
tammy.dupreez@cleafy.com
About QKS Group
QKS Group is a global analyst and advisory firm helping enterprises, technology vendors, and investors make trusted, data-driven decisions. Our portfolio spans the flagship SPARK Matrix™ evaluation framework, SPARK Plus™ analyst advisory platform, QKS Intelligence™ for market and competitive tracking, and QKS Community™ for CXO leaders and practitioners. All offerings are powered by a Human-Intelligence-driven framework and QKS’s closed-loop research methodology – integrating expert-led insights, quantitative modeling, and continuous validation to deliver credible, outcome-focused intelligence.
For more available research, please visit Research
Media Contact:
Anish Krishnan
PR & Media Relations
QKS Group
5th Floor, Wing 2, Cluster C,
EON Free Zone, Kharadi,
Pune, India
Email: support@qksgroup.com
Content Source: https://qksgroup.com/newsroom/cleafy-named-a-leader-in-qks-group-spark-matrix-enterprise-fraud-management-2026-1844
Connect with us on LinkedIn- https://www.linkedin.com/company/qksgroup/
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/cleafy-named-a-leader-in-qks-group-spark-matrix-enterprise-fraud-management-2026-302926290.html
Technology
LianLian Global and Cobre Collaborate to Streamline China-Latin America Payments
Published
3 minutes agoon
November 2, 2026By
HONG KONG, Nov. 2, 2026 /PRNewswire/ — LianLian Global, the cross-border payment brand of Hong Kong-listed Lianlian DigiTech, today announced a collaboration with Cobre, the leading platform for instant business payments in Latin America, to power cross-border payments between China and Latin America.
Through this collaboration, LianLian Global clients can reach Cobre’s local payment infrastructure in Latin America, and Cobre clients can process fast, compliant payouts into China through LianLian Global’s licensed network.
Trade between China and Latin America reached approximately US$565 billion in 2025, up 6.5% year on year, according to China’s General Administration of Customs. Yet cross-border payments supporting this trade can involve multiple correspondent banks, adding costs and delays.
By combining LianLian’s licensed China payout capabilities with Cobre’s local infrastructure in Latin America, this collaboration gives businesses on both sides a more direct way to settle cross-border payments. The collaboration aims to reduce the number of intermediaries involved, lower payment costs and shorten settlement times. This collaboration also aims to provide transparent foreign exchange (FX) pricing and end-to-end payment tracking across both the collection and payout legs.
Bryan Jiang, General Manager of LianLian Global in Hong Kong, said:
“Latin America is one of the fastest-growing markets for us, and Cobre has built the local infrastructure needed to serve that market. With this collaboration, we can offer businesses on both sides a faster, more transparent way to make cross-border payments along the China–Latin America corridor.”
Jose Gedeón, CEO and Cofounder of Cobre, added:
“Latin American enterprises engaging in commerce require heightened speed and predictability in their transaction flows. Our work with LianLian Global allows us to provide just that.”
James Wong, Senior Vice President (Financial Services and Fintech) of InvestHK, said:
“Hong Kong has long served as a gateway between Asia and the rest of the world, and Latin America is a growing part of that story. We are pleased to see LianLian Global and Cobre working together to make cross-border business payments between both regions faster and simpler, leveraging our flagship HK Fintech Week to mark the start of the collaboration”.
As trade between Asia and Latin America deepens, both companies plan to extend the collaboration to additional payment corridors and use cases.
About LianLian Global
LianLian Global is the international brand of Lianlian DigiTech Co., Ltd. (HKEX: 2598) (“Lianlian”), a global payment and financial platform founded in 2009 and listed on the Main Board of the Hong Kong Stock Exchange in 2024.
Lianlian has served more than 13.3 million clients. Its services reach more than 200 countries and regions, support transactions and settlements in more than 140 currencies, and connect with more than 180 global e-commerce platforms. Lianlian holds 68 payment licenses and related authorizations worldwide, alongside a Hong Kong virtual asset trading platform (VATP) license.
About Cobre
Cobre is the leading enterprise payments infrastructure for Latin America, enabling businesses to move money faster across Latin America and the world. Cobre operates in Colombia and Mexico, offering three core solutions: Local Payments, Cross-Border Payments and Stablecoin Payments. In 2025, Cobre processed over US$17 billion in payment volume across 28 million transactions, serving more than 300 enterprise clients and achieving profitability. Trusted by leading fintechs, financial institutions, and multinational enterprises, Cobre helps businesses simplify financial operations and scale across Latin America.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/lianlian-global-and-cobre-collaborate-to-streamline-china-latin-america-payments-302926292.html
SOURCE Lianlian DigiTech
Northwood raises $375 million to build the network connecting satellites to Earth
Cleafy Named a Leader in QKS Group SPARK Matrix™: Enterprise Fraud Management, 2026
LianLian Global and Cobre Collaborate to Streamline China-Latin America Payments
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Coin Market3 days agoBinance hack may involve private key ‘misuse,’ not theft: Blockaid CEO
-
Coin Market4 days agoCanton Foundation grants RedStone 15.8M Canton Coin for pricing standard
-
Technology4 days agoMoonello Shifts Focus to AI and Software Engineering, Introduces Four Fixed-Fee Services
-
Technology4 days agoAppian Defense Cloud Achieves IL5 Authorization Across Department of War Operations
-
Technology3 days agoFrom Catapult to capital: NextFin Asia reaches first investment milestone with Indonesia’s Finfra
-
Technology4 days agoUnited Premier Soccer League Names Corgi Insurance Its Official Insurance Partner
-
Technology3 days agoThirty Weihai Companies Added to Shandong’s Green Factory List
-
Technology3 days ago
Thirty Weihai Companies Added to Shandong’s Green Factory List
